The effort, called SepTech, will begin on Sept. 1 and run through August 2029, and it picks up from an earlier project called ...
The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.
The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share, noting their strong positions in non-oncology markets and recent moves into cancer testing.
With ongoing reagent challenges postponing its proteome-scale ambitions indefinitely, the firm has shifted the majority of its R&D resources to developing its targeted technology.
A polygenic risk score provided insights into hypertrophic cardiomyopathy risk and adverse cardiovascular outcomes in individuals with or without Mendelian disease contributors.
The program aims to bolster domestic biomanufacturing and supply chain capabilities and speed point-of-care therapeutics production.
The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.
The Fitrapid test is a noninvasive at-home kit designed to detect fecal occult blood, an early warning sign of lower gastrointestinal tract diseases.
NEW YORK – TCM Biotech said Tuesday that it has received US Food and Drug Administration breakthrough device designation for its Catchimera minimal residual disease (MRD) test for hepatocellular ...
Top Five Articles Last Week: Antibody Image Manipulation, Guardant Health to Pay $245M Damages, More
NEW YORK – Which articles gained the most attention from GenomeWeb’s readers last week? Here are the top five: New Report Details Widespread Antibody Validation Image Manipulation Across the Industry ...
Bio-Techne filed suit against Molecular Instruments in 2024, alleging that the company infringed Bio-Techne's RNAscope in situ hybridization technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results